Table 3.

Outcomes of NIH-CPSI and IIEF-5 in CPPS and control groups.

Characteristics	All subjects (N = 1280)	CPPS (N = 801)	Control (N = 479)	P
NIH-CPSI (scores)
Total scores	20.25 ± 6.52	31.23 ± 9.86	1.89 ± 1.17	<0.001
Pain symptoms	10.49 ± 4.47	16.34 ± 5.25	0.72 ± 0.25	<0.001
Urinary symptoms	5.27 ± 2.18	8.03 ± 3.13	0.65 ± 0.33	<0.001
Quality of life impact	4.49 ± 1.92	6.86 ± 2.24	0.52 ± 0.19	<0.001
IIEF-5 (scores)
Total score	19.77 ± 3.62	17.70 ± 3.25	23.23 ± 3.84	<0.001
Q1	3.67 ± 0.82	3.02 ± 1.15	4.75 ± 0.62	<0.001
Q2	3.68 ± 1.02	3.16 ± 1.07	4.56 ± 0.78	<0.001
Q3	4.13 ± 0.95	3.89 ± 0.72	4.52 ± 1.02	<0.001
Q4	4.35 ± 0.67	4.11 ± 0.43	4.74 ± 0.82	<0.001
Q5	3.95 ± 0.94	3.52 ± 1.24	4.66 ± 0.75	<0.001

Data are expressed as the mean ± standard deviation.

Differences between CPPS and control groups were assessed by Mann-Whitney U test.

NIH-CPSI = National Institute of Health-Chronic Prostatitis Symptoms Index; CPPS = chronic pelvic pain syndrome; PE = premature ejaculation; IIEF-5 = International Index of Erectile Dysfunction 5.

P: difference between CPPS and control groups.